May 06, 2026 

Something unprecedented just happened in Washington D.C… 

FEATURED: Eli Lilly’s Numbers Are Exceptional  Sponsored

Editor’s Note: Please read the following note from 60-year Wall Street veteran Marc Chaikin, who explains what Fed Chair Powell’s recent emergency meeting – called in response to a major AI lab breakthrough – could mean for your wealth.

---

Dear Reader,

Something unprecedented just happened in Washington D.C…

And the ripple effects could hit your money in a major way.

Treasury Secretary Scott Bessent and Fed Chair Jerome Powell recently summoned the CEOs of America’s biggest banks to an emergency meeting.

Why?

One AI lab just built an innovation so powerful… the Fed, Treasury, and virtually every major bank on Wall Street believes it could reshape the entire U.S. financial system.

That’s why the U.S. government is rushing to deploy this technology across every major federal agency…

And why every major bank on the planet is now racing to get their hands on it.

JPMorgan is already in. So is Bank of America.

Goldman Sachs is even setting it to work on their most complex, back-office operations.

In other words, the U.S. government and the most powerful financial institutions in the world are begging one private AI lab for access to their technology.

And right now, there’s still a little-known way to claim a backdoor stake in this private firm for less than $40 – before what could be the biggest IPO of the year.

I’ve put together a full presentation with the details – including the name and ticker – free of charge.

But please don’t delay. This profit window closes on June 16.

Click here to watch now.

Regards,

Marc Chaikin
Founder, Chaikin Analytics

P.S. My award-winning system turned BULLISH on every member of the Magnificent Seven before they soared spectacularly…

Like Tesla in 2017 before it soared as much as 2,915%…

And Nvidia in 2014 before it soared as much as 55,000%.

Now it’s flashing BULLISH on a little-known “pre-IPO backdoor” into the most sought-after private AI firm in the world.

Best part of all? It trades for less than $40 a share.

Click here to see why I recommend swinging into action before June 16.

FEATURED

Eli Lilly’s Numbers Are Exceptional 

Eli Lilly and Company (LLY) entered 2026 as one of the most watched large-cap equities on the planet – and the first four months have done nothing to quiet the conversation. After a significant pullback from its all-time high of $1,133.95 that took shares down toward the low-$600s earlier this year, LLY has staged a forceful recovery. As of May 6, 2026, the stock is trading near $988, powered by a Q1 earnings report that wasn’t just good – it was the kind of print that resets the analytical conversation entirely.

The Macro Backdrop: A Different Picture Than Earlier This Year

The macro environment has shifted meaningfully from the first-quarter pressure that drove high-multiple healthcare names lower. The Federal Reserve held the federal funds rate steady at 3.5% to 3.75% at its April 28–29 FOMC meeting – the third consecutive hold – following a series of rate cuts executed in late 2025. The 10-year Treasury yield is hovering near 4.39% to 4.44%, down from the more elevated levels that compressed growth multiples earlier in the year. That’s still not zero, but it’s a meaningfully different backdrop than what was pressuring the stock in Q1.

The Fed meeting itself was notable for internal friction – the April decision saw four dissenting votes, the most since 1992, with debate centering on whether additional rate increases might be warranted if inflation data deteriorates further. Middle East tensions have introduced an energy price wildcard that is keeping the Fed cautious. That uncertainty hasn’t disappeared, but market participants appear to have largely priced it in. For now, growth-oriented healthcare names are getting their footing back. Sponsored

Massive 512,000-Line Data Leak Exposes Shocking AI Breakthrough

60-year Wall Street veteran and financial technology pioneer Marc Chaikin recently reviewed a massive data leak inside one of the world’s biggest AI labs. He discovered a hidden mechanism in the code that could create extraordinary wealth for savvy investors – and inflict grave financial hardships on everyone else.

Click here for the full story.

Q1 2026 Results: The Numbers Are Hard to Argue With

Lilly reported Q1 2026 results on April 30, and the print was exceptional by almost any measure. Total revenue came in at $19.8 billion, up 56% year-over-year, driven by volume growth that outpaced even the most optimistic sell-side models. Adjusted EPS hit $8.55, against a consensus expectation of $6.66. Shares rose more than 10% in afternoon trading the day of the release.

• Mounjaro global revenue reached $8.66 billion in the quarter, more than doubling year-over-year. U.S. revenue was $4.2 billion (+59%), with international contributing $4.4 billion – up from just $1.2 billion in Q1 2025, driven by expansion into Europe, China, and Brazil.
• Zepbound U.S. revenue hit $4.16 billion, up 80% from the year-earlier period, beating analyst estimates of $4.04 billion. Volume surged even as realized prices declined on lower cash-pay pricing.
• Combined Mounjaro and Zepbound revenue totaled $12.8 billion for the quarter – a franchise that, annualized, would rank among the largest revenue-generating product lines in pharmaceutical history.
• Gross margin came in at approximately 81.9% on a reported basis, slightly lower year-over-year due to pricing pressure, but still exceptional in absolute terms and consistent with Lilly’s premium profile.
• Lilly holds 60.1% share of the U.S. obesity and diabetes GLP-1 market, versus Novo Nordisk’s 39.4%, according to the company’s own earnings presentation.

Following the beat, Lilly raised its full-year 2026 revenue guidance to $82 billion to $85 billion, up $2 billion from the prior range. Full-year adjusted EPS guidance was lifted to $35.50 to $37.00, from $33.50 to $35.00. International expansion – particularly in markets where patients are paying out of pocket across Europe, China, and Brazil – is now hitting stride and represents a material new growth driver that wasn’t a significant contributor twelve months ago.

Foundayo: The Oral GLP-1 Launch Changes the Narrative

One of the biggest structural developments in the Lilly story is no longer a future catalyst – it’s already happening. The FDA approved Foundayo (orforglipron) on April 1, 2026, making it the only GLP-1 pill approved for weight loss that can be taken any time of day without food or water restrictions. Retail pharmacy availability began April 9. More than 20,000 people started taking Foundayo in the first few weeks after launch, and commercial copays were structured as low as $25 per month for insured patients.

Slight tangent, but it matters: Foundayo is a small molecule, which means it doesn’t require refrigeration, complex administration, or the cold-chain infrastructure that has constrained injectable GLP-1 distribution globally. CEO Dave Ricks has been explicit that Foundayo is the vehicle for scaling Lilly’s reach to markets where Zepbound logistics are prohibitive. That’s not a two-quarter story – it’s a multi-year expansion opportunity that is only beginning to show up in the data.

Foundayo is also not as potent as Zepbound. Clinical trials showed average weight loss of approximately 12.4% at the highest dose, versus the 20%-plus body weight reduction tirzepatide has demonstrated. Novo Nordisk’s oral Wegovy showed 16.6% in its trial. That efficacy gap is real and will matter to some patients and prescribers. Lilly’s argument is that convenience and accessibility expand the total addressable population more than they cannibalize the existing injectable market – and early prescription data is being watched closely to validate or challenge that thesis.

Valuation After the Recovery

At $988, the valuation conversation is different than it was when the stock was in the low-$700s. The multiple has reexpanded.

• Forward price-to-earnings at current levels: approximately 27 to 28 times 2026 guidance midpoint of $36.25 in adjusted EPS. That is a meaningful compression from the peak multiple near 55 times, but also a significant rerating from the oversold lows.
• The 52-week range spans from a low of $623.78 to a high of $1,133.95. At $988, the stock is trading approximately 13% below its 52-week high and roughly 58% above its 52-week low – a recovery that reflects how severely the market had discounted the fundamental trajectory.
• At current prices and guidance, the revenue multiple on 2026 estimates sits near 11 to 12 times – elevated relative to traditional pharma, but more defensible given the 56% growth rate posted in Q1 and the scale of the pipeline.
• Nineteen analysts maintain a Buy consensus rating with an average 12-month price target near $1,204, implying approximately 21% upside from current levels.

 SponsoredSpaceX IPO 2026: What Investors Need to Know Now

SpaceX is still private, but credible reports and rising valuations suggest momentum may be building. If a filing happens, markets could move quickly. This Special Reportbreaks down what is confirmed, what is not, and the signals investors are watching closely right now.

Read the Special Report

The bear argument is not that Lilly is operationally broken – it clearly isn’t. The concern is that a 28-times forward multiple on a pharmaceutical company still prices in a significant growth premium, and any stumble in prescription trends, formulary dynamics, or pipeline execution gets amplified at that valuation. The Foundayo liver safety questions circulating in some analyst notes are worth monitoring, even if they aren’t yet material. At this price, there is less margin for error than there was at $650.

Pipeline Depth: Beyond the GLP-1 Conversation

Serious analysis of Lilly’s investment case can’t stop at tirzepatide and Foundayo. The pipeline carries multiple assets with commercial potential that are not yet fully reflected in base-case models.

• Kisunla (donanemab) for Alzheimer’s disease is now established in the market as the only amyloid-targeting therapy with evidence supporting stopping treatment once plaques are removed. Uptake is building as diagnostic infrastructure for early-stage Alzheimer’s expands. European launches are expected to begin contributing to growth through 2026.
• Ebglyss (lebrikizumab) for atopic dermatitis reported four-year durability data in March 2026 showing sustained disease control in the majority of patients, and positive Phase 3 results in pediatric patients were also reported – a potential label expansion into a new population.
• Retatrutide, a triple GIP/GLP-1/glucagon agonist in Phase 3, reported positive topline results in type 2 diabetes in March 2026, with up to 16.8% weight loss at 40 weeks. If the obesity Phase 3 program confirms what earlier data suggested, retatrutide could represent the next step-change in metabolic disease treatment beyond tirzepatide.
• Foundayo itself is in Phase 3 trials for type 2 diabetes, with Lilly planning to file for that indication before the end of Q2 2026. An expanded label would materially broaden the addressable patient population.
• Lilly completed four acquisitions in Q1 2026 alone – Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics – reflecting management’s active posture toward augmenting the internal pipeline across oncology, neuroscience, and rare disease.

Technical Structure: Where the Stock Stands

From a technical standpoint, LLY’s post-earnings recovery has been sharp. The stock broke down significantly from its 2024–2025 highs, traded into the low-$600s during the worst of the Q1 macro pressure, and has now staged a recovery that has brought it back toward the $1,000 level. That is not a small move – it reflects a fundamental re-anchoring of expectations following a quarter that exceeded even the more constructive sell-side models.

Near-term resistance sits at the psychologically significant $1,000 level, and more meaningfully at $1,050 to $1,100, which corresponds to the zone where the 2025 breakdown accelerated. A sustained reclaim of $1,000 on volume would be a structural positive. On the downside, support is now being rebuilt around $940 to $960, with a more significant level near $880 to $900 where volume accumulated during the recovery phase. The all-time high of $1,133.95, set in late 2025, remains the longer-term reclaim target for any structural bull thesis.

Options implied volatility has remained elevated relative to historical norms, which means the cost of defined-risk structures is higher than in calmer periods – but it also means the market is still pricing in meaningful uncertainty around near-term outcomes. That is worth accounting for in position sizing regardless of directional conviction.

Scenario Modeling From Here

Bull Case

Foundayo prescription volumes ramp meaningfully through Q2 and Q3, international Mounjaro penetration continues to accelerate, and retatrutide Phase 3 obesity data confirms the weight loss profile suggested by earlier trials. In that environment, shares could retest the $1,100 to $1,133 range and potentially challenge prior highs into year-end as analysts revise 2027 estimates upward. A Medicare GLP-1 Bridge program launching by July 1, 2026 – which CMS has confirmed, capping out-of-pocket costs at $50 per month for seniors – adds a structural demand catalyst that hasn’t yet shown up in prescription data.

Base Case

Revenue growth continues at the high end of guidance, Foundayo ramps gradually as payer coverage expands, and the stock consolidates in the $940 to $1,050 range through the summer as investors assess competitive dynamics between oral GLP-1 products. Valuation stabilizes around 26 to 28 times forward earnings, and shares grind modestly higher through the second half of 2026 as additional pipeline data points arrive.

Bear Case

Foundayo faces formulary access challenges or the liver safety questions cited in some analyst notes prove to be more than noise, Novo’s oral Wegovy erodes Lilly’s market share faster than expected, or macro conditions deteriorate on energy price shocks tied to Middle East instability. A sustained move below $880 would suggest the recovery has stalled and would open a path toward retesting the $800 area. That scenario requires multiple things going wrong simultaneously – but it is not zero probability given current geopolitical uncertainty.

Active Trader Framework

The dynamics here have shifted from the deep-value, oversold entry setup that existed when the stock was in the $650 to $720 range. At $988, traders are working with a stock that has already made a large move and is now approaching meaningful resistance. That changes the risk-reward calculus.

Key levels: $1,000 is the near-term psychological and technical pivot. A clean break and hold above $1,000 on volume opens the path toward $1,050 to $1,100. Failure to reclaim $1,000 after multiple attempts would set up a consolidation range with downside risk back toward $940. Prescription data releases, any updates on Foundayo’s formulary coverage trajectory, and the next Fed meeting will be the primary catalysts for directional movement in the weeks ahead.

Risk management discipline remains essential. A stock that moves 10% in a single session on earnings – which LLY just did – has a volatility profile that demands appropriate position sizing regardless of conviction level. The fundamental case is strong. That doesn’t mean the path higher is linear.

---

Lilly at $988 is a different conversation than Lilly at $715 – the valuation has reexpanded, the easy money from the oversold recovery has largely been made, and the next leg of the thesis depends on execution across a broader set of products than just Mounjaro and Zepbound. The pipeline is deep, the franchise momentum is real, and management has been consistent in its ability to deliver. But at this price, the margin for error is narrower. That’s where the work actually begins.

For informational and educational purposes only. Not investment advice. Trading involves risk, including loss of principal.

This content is for informational purposes only and should not be considered financial advice. Investing involves risk.

The Cheap Investor is a publication of Investing Media Solutions, LLC.

_{To view our full policies: Disclaimer | Privacy Policy | Terms & Conditions}

Update your email preferences or unsubscribe here

© 2026 The Cheap Investor 

203 N La Salle Suite 2100
Chicago , Illinois 60601, United StatesPowered by beehiivTerms of Service 

Learn More About Adoration of the Child

Today’s Night Prayer is brought to you by Catholic Coffee

A Night Prayer

Jesus Christ, my God, I adore You and thank You for all the graces You have given me this day. I offer You my sleep and all the moments of this night. I place myself and all my loved ones, wherever they may be, in Your sacred side and under the mantle of Our Blessed Mother. Let Your holy angels stand watch and keep us in peace. Amen.

Quote of the Day

“For where your treasure is, there your heart will be also.” -Matthew 6:21 

Today’s Meditation

“Think of all of our omissions with regard to opportunities for and impulses toward prayer. All those free moments we have in the course of each day: we could use them for prayer, but we omit to do so…Think of all the inspirations of grace and all the impulses to good we neglect or to which we turn a deaf ear. We know that God is speaking to us in them and moving us, urging us on to do good. A writer on the spiritual life says: “Our hope of making progress in the interior life depends entirely on the inspirations of God,” that is to say, on how we attend to them and follow them.” —Benedict Baur, p. 162

An excerpt from Frequent Confession: Its Place in the Spiritual Life

The Perfect Pairing For Night Prayer

Relax with a rich cup of coffee that inspires you to aim for Heaven.

Browse our coffee that pairs each artisanal roast with a heavenly patron. With blends like St. Thomas Aquinas Honey Blend, St. Patrick’s Irish Cream, and St. Michael Dark Roast, there’s a selection for every Catholic coffee lover. Now available as K-cups!

Want to enjoy a hot cup while reading Night Prayer without risking beauty sleep? There’s a decaf roast, too! Check out Sleeping St. Joseph Decaf.See Them All 

Recommended Products

Sacred & Immaculate Hearts Cathedral Window Framed Print

Manual for Eucharistic Adoration

Examination of Conscience

The daily examination of conscience is an ancient Catholic practice. It’s very simple, and it’s designed to help us identify our sins and weaknesses so that we can improve and grow stronger in the spiritual life, while providing an excellent ongoing preparation for regular Confession. It consists of taking a few minutes at the end of the day to prayerfully review our actions in the light of God’s commandments, followed by the Act of Contrition.

 Reflect on the victories and losses

Actively reflecting on the high and low points of the day can help you live more intentionally and bring a renewed sense of resolve into the following day.

• Review your actions, words, and thoughts today. Did you actively guard yourself against temptation? Where did sin creep in?
• In what moments did you practice virtue and moral courage?
• Were you attuned to the Holy Spirit’s promptings today? Where did you feel His inspiration?
• Ask Him for the graces necessary to follow His Will more purposefully tomorrow.

 Act of Contrition

O my God, I am heartily sorry for having offended Thee, and I detest all my sins because of Thy just punishments, but most of all because they offend Thee, my God, Who art all good and deserving of all my love. I firmly resolve with the help of Thy grace to sin no more and to avoid the near occasions of sin. Amen.

 Practice gratitude

It is God’s love that has brought you into existence and to this exact moment. Practice looking for His hand in your day. 

• Where did you feel His loving gaze upon you today?
• What people or moments helped you see God in your life?
• Thank God for all these moments!
• Ask Him to help you recognize His blessings and providence tomorrow.

 Renew your commitment to Christ

Remember: our Faith is founded upon a Person—Christ! Renew your personal love and devotion to Him.

• Thank God for the gift of His Son Jesus and our call to be His disciples.
• Tell the Lord of your desire to know Christ more personally.
• If possible, set an intention for your day tomorrow. Ask Our Lord to guide you in this act.
• Pray a Hail Mary, Our Father, or another beloved prayer.

Rest with God

He determines the number of the stars, He gives to all of them their names. — Psalm 147:4

Compline

Read Now 

Want to help your organization reach 2.6 million Catholics? Click here to consider sponsoring future Night Prayers!

Please add NightPrayer@goodcatholic.comto your address book or list of approved senders.

Unsubscribe | Privacy Policy | Contact Us

Can’t see this email? View in Your Browser

A service of the Network

615 E Westinghouse Blvd Charlotte, North Carolina 28273 US

© 2026 Trinity Road, LLC. All rights reserved.

UnsubscribeTicker Revealed: Pre-IPO Access to “Next Elon Musk” Company (From Banyan Hill Publishing)

How Williams Companies Is Cashing in on the AI Power Boom

Written by Chris Markoch

Williams Company Inc. (NYSE: WMB) moved up a modest 1% after delivering mixed headline numbers in its Q1 2026 earnings report. The company delivered adjusted earnings per share (EPS) of 73 cents, easily beating expectations of 63 cents. However, revenue was a slight miss with Williams delivering $3.03 billion, below expectations of $3.28 billion.

Some context is required. For midstream infrastructure companies like Williams, revenue can be misleading due to commodity pass-through accounting. A more relevant metric of a company’s health is adjusted EBITDA. And that’s an area where Williams shone, reporting a record $2.25 billion.

The key takeaway from the report is that demand for natural gas far exceeds supply. The company cited research that natural gas demand will increase by 35% in the next decade. It’s a structural tailwind for WMB to move higher, even as it approaches its consensus price target and the top of its 52-week range.

Williams Doesn’t Directly Export LNG, But…

Natural gas companies are getting a tailwind from the supply disruptions in the Middle East, which are increasing demand for LNG from the United States. That’s not going to impact Williams directly, as its transmission pipelines are confined to the continental United States.

But the company does have an acquired interest in Louisiana LNG. That gives the company fixed-fee revenue tied to that export market. Also, the company’s Transco pipeline corridor is a primary gas artery for Gulf Coast LNG facilities. This is a specific, concrete relationship that positions Williams to benefit from expanding Gulf Coast export capacity.

Data Centers Hold the Key to Long-Term Demand

The data center opportunity may be the most underappreciated element of the Williams growth story. The company is investing approximately $9.6 billion in behind-the-meter power projects. That means it is essentially building turnkey natural gas power plants directly connected to hyperscaler data centers, bypassing the traditional grid entirely.

The portfolio includes six named projects: Socrates, Apollo, Aquila, Socrates the Younger, Neo, and Atlas, with in-service dates ranging from late 2026 through 2028. Combined ISO capacity across these projects exceeds 2,500 megawatts, under agreements ranging from 10 to 12.5 years. Williams also has approximately 6 gigawatts of additional projects in its backlog.

The strategic logic is straightforward. Hyperscalers need power that is fast to deploy, always on, and independent of grid constraints. Renewables cannot currently meet that standard without massive battery storage infrastructure that doesn’t yet exist at scale.

Williams is positioning itself as the answer to that gap. Instead of simply moving gas, this means Williams is embedding itself directly into customer infrastructure under long-term contracts.

The company’s backlog of approximately $15.5 billion between 2027 and 2033 accounts for about 18 months of current revenue. That’s a good reason to believe there’s a higher floor for WMB.

But how high is the ceiling? WMB is butting up to its consensus price target of roughly $79. Analysts have been slow to update their ratings and price targets since the report. However, since the company’s Q4 earnings report, a handful of firms have raised their price targets. The most bullish comes from Morgan Stanley (NYSE: MS), which raised its target to $90 from $83.

How Concerned Should Investors Be About the Debt?

The one area of the report that investors shouldn’t be too quick to dismiss is the company’s growing capital expenditures (CapEx). The new midpoint of $7.3 billion has pushed the company’s leverage to approximately 4.1x. That’s only a tick above the company’s target of between 3.5 to 4x.

In a vacuum, the number isn’t a concern. Williams has an investment-grade balance sheet and laddered maturity levels. However, in 2008, WMB was rocked after a credit shock hit the market, catching the company offside. While a credit shock of that magnitude seems unlikely, the risk of a mild credit shock is not zero.

That said, there’s probably an appropriate level of concern to apply to the company’s elevated debt level. It’s not zero, but it’s not a high-priority concern.

The heavy capital investment is front-loaded into the current calendar year. And on the earnings call, the company noted that the projects coming online in 2027 and 2028 will generate new EBITDA, helping reduce the leverage ratio before active debt paydown begins.

Maybe Not a Stock to Hold Forever, But a Strong Performer for Now

The continued buildout of renewable energy projects, specifically solar and battery storage, is a real threat to Williams. However, the threat is likely not a significant one to the business until 2035 or later.

At that point, battery storage at grid scale will become economically competitive with natural gas. It’s also when the company’s current wave of LNG export contracts begins to roll off. Adding to the bear case is that the timeline also roughly coincides with the company’s longer-dated transmission contracts coming up for renewal.

These three headwinds converging around the same horizon are worth monitoring. If any one of them accelerates faster than expected, that 2035 timeline could compress. But what may happen in the future isn’t the same thing as what’s happening right now. For now, Williams looks like a solid choice for income and growth during this unprecedented period of natural gas demand. READ THIS STORY ONLINE

URGENT: $2 Gold Stock With Major Discovery (Ad)

A $2 gold stock is said to quietly control what may be the largest gold deposit in the world – worth nearly $1 trillion.

According to Jim Rickards, an announcement is expected around July 1that could bring this historic discovery into public view.SEE THE FULL DETAILS ON THIS $2 GOLD STOCK BEFORE JULY 1

DigitalOcean’s AI Surge: How Far Can This Rally Go?

Written by Thomas Hughes

Digital Ocean (NYSE: DOCN) is an AI infrastructure play potentially beyond compare. It not only owns and operates a network of high-performance data centers but also has the software stack to support them. It is a cloud computing solution for small and medium-sized businesses, enabling them access and scalability alongside ease of use, and the business is gaining traction. Plans include expanding its footprint over the coming year, driven by a rising tide of AI demand; the question for investors is how high this AI play can go.

DigitalOcean Accelerates, Outperforms, and Raises Guidance

DigitalOcean had a solid Q1 earnings report, with revenue growth topping 22%, accelerating sequentially and compared to the prior year.

Revenue outpaced the consensus by a substantial margin, indicating a fundamental misunderstanding of the growth opportunity, and is expected to continue accelerating in the upcoming quarters. Growth was driven by large clients and AI demand, with annual run-rate revenue (ARR) from large clients up by 180% and AI-related ARR up by 221%.

Margin news was mixed, with margin contracting in some comparisons and expanding in others. The critical details are that the core business is profitable, profitability improves with scale, and weaknesses are tied to spending increases. Spending increases aim to increase capacity and underpin management’s decision to increase guidance. They now expect at least 50% revenue growth in the subsequent fiscal year and may be cautious in the estimate. The company is already expanding its footprint, and pricing is a factor to consider as well. Demand for GPU capacity is driving rental prices through the roof, and DigitalOcean is exposed to the market.

Strong Market Getting Stronger, But Upside May Be Limited

The MACD indicator suggests that this rally is just getting started. It is a measure of market momentum and can be used to gauge whether a market is strengthening or weakening. In this case, the convergence between the MACD peak and price action suggests the market is strengthening and likely to continue higher over the long term, with periodic corrections aside.

Analysts, institutions, and valuation suggest the upside may be limited, but they are not the only factors in play. Analysts rate the stock as a conviction Moderate Buy with 75% Buy-side bias, but price action has outpaced the consensus price target. The likely outcome is that DOCN stock price corrects at some point, touching base with the consensus level before continuing its advance in the longer term. Additionally, institutions were selling heavily in late 2025 and early 2026, which presents a headwind for the market and could amplify any correction that forms.

Valuation is the biggest concern, as the stock trades at over 125X its current-year earnings forecast. The market is pricing in a robust outlook, but even so, valuation is expected to fall only slightly over the next few years, leaving the stock highly valued relative to its forecasts and tech peers. The worst-case scenario is that this company fails to meet its outlook, leading to a market reset and a massive stock price correction, but that is unlikely given the recent Q1 results and the guidance update.

2 Catalysts for DOCN Price Action May Strengthen

While analysts and institutions limit the upside potential, they also provide support for this market. The market has outrun the consensus price target, but the trend remains positive, with recent revisions leading it into the high end of the range. Those revised price targets would be sufficient for more than 30% upside from the $150 level, where the DOCN stock price surged following the report. Institutions, on the other hand, sold heavily in early 2026 but reverted to buying in early Q2 and may continue to accumulate as the quarter progresses.

Catalysts for this stock include its aggressive expansion. The plans include more than tripling total capacity by early 2028, potentially driving revenue growth into the triple-digit range and sustaining it for several quarters. Risks include the cost of buildout, including a nearly-$1 billion equity raise, and the threat of dilution. As it stands, the share count is up approximately 10% at the end of Q1, and though the company is well-capitalized, additional funding is not out of the question. Delays, missteps, and cost-overruns will be reflected in the stock price.

DigitalOcean is leaning on debt to fundits expansion, and its balance sheet can handle the load. Highlights at Q1’s end include increased cash, current and total assets, with long-term debt and liabilities declining, equity improving, a net-cash position, and low total leverage. The likely outcome is that cash flow will enable debt reduction as the buildout progresses, with cash flow increasing over time and equity rising alongside it. READ THIS STORY ONLINE

Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company (Ad)

We’ve found The Next Elon Musk… and what we believe to be the next Tesla. 

It’s already racked up $26 billion in government contracts.

Peter Thiel just bet $1 Billion on it.👉 UNLOCK THE TICKER NOW AND GET IT COMPLETELY FREE.

Capital One’s Big Bet Faces Rising Credit Risk

Written by Peter Frank

It’s complicated, but just you wait. That’s the message from Capital One (NYSE: COF) in light of its first-quarter results as it undertakes a significant rejiggering of its business.

For many investors, that’s not been a convincing argument. The lender’s stock has fallen more than one-third since early January. But analysts expect the shares to rebound. Investors trying to decide whether the recent selloff is a red flag or a buying opportunity need to pick through the numbers carefully.

Capital One’s Road to Payments Giant

Capital One is arguably one of the most closely watched bets in American banking. When the company completed its takeover of Discover in May 2025, it bought more than a credit card company. It got its own payments network.

Instead of running its cards on the Visa (NYSE: V) or Mastercard (NYSE: MA)platforms, which charge merchants interchange fees, Capital One can route transactions on its own rails, potentially saving billions over time. 

The combined company now lands solidly among the top four payment networks in purchase volume with Visa, Mastercard, and American Express (NYSE: AXP).

From the deal, management has promised more than $2.5 billion in annual synergies, including $1.5 billion from cost savings and $1.2 billion from network efficiencies. 

Much of that might not show up until 2027, after the planned technology merger and migration of customers.

That’s the idea, but the first-quarter results told a more complicated story.

Earnings Missed Expectations

For the first quarter, Capital One reported adjusted earnings of $4.42 per share, missing analyst expectations of $4.61 per share. Revenue surged 52.3% year-over-year to $15.23 billion, thanks in large part to the contribution of Discover. But even that fell short of Wall Street forecasts.

The number that caught much of the attention, though, was net interest margin, which sank to 7.87%, down 39 basis points from the prior quarter. That measure of the difference between what a bank earns on its loans and what it pays on deposits again disappointed.

For its part, the company blamed fewer calendar days in the first quarter compared with the last three months of 2025 and the seasonal impact of customers paying down debt after the holidays. But strong retail deposit growth and the impact of the company’s sale of the Discover Home Loans portfolio also factored in.

There was some good news. Earnings before the bank set aside reserves for potential troubled loans rose 8% quarter over quarter to $6.8 billion. And signs that integration was coming along led to non-interest expenses falling 9% to $8.5 billion, and marketing spend dropping 23%.

Credit Losses Keep Climbing

Still, other trends were troubling. Capital One’s provision for possible credit losses surged 72% YOY to $4.07 billion—again coming in higher than analyst estimates. Overall, net charge-offs reached $3.8 billion for the quarter, up 41% YOY.

This is not the direction investors wanted to see. Capital One’s core business is consumer credit cards, and its customers have historically skewed toward subprime and near-prime borrowers. Even with Discover’s more affluent consumer profile, stressed household budgets with elevated inflation and interest rates could keep Capital One’s loan losses eating into earnings.

In fact, management’s decision to build reserves by an additional $230 million, most notably in auto and consumer banking, could suggest possible tough conditions ahead.

Capital Levels Provide Some Protection

The company does have room to cushion surprises. Capital One’s Tier 1 capital ratio stands at a healthy 14.4% and is in line with many in the financial sector. And while the dividend yields just 1.7% annually on a payout of $3.20 per share, the board has approved a $16 billion buyback plan near the end of last year.

The bank’s efficiency ratio, which is a measure of how much it spends to generate each dollar of revenue. stood at 55.57%. That’s not bad for retail banks with large branch networks, but above the sub-50% levels enjoyed by many digital-first banks. Still, the level trended down from the previous and YOY quarters, and the gap suggests some redundancies still exist. The migration of Discover’s credit card customers onto Capital One’s technology platforms, if completed as planned, could provide some relief for these numbers.

The Discover Deal Must Deliver

The central question still is whether the Discover acquisition will deliver on its promises. The strategic logic of the Discover deal is clearly there. Owning a payment network may help expand the combined brands’ merchant acceptance globally, which is a lingering soft point, and could unlock substantial revenue.

But the integrations and cost savings need to arrive. That becomes even more interesting as Capital One also picked up another business in April when the lender closed on a $5 billion for Brex.

That additional strategic pivot moved the company even further beyond its traditional consumer business. Brex, a fintech platform that provides business payments and spend management services, delivers to Capital One an AI framework designed to automate accounting workflows. Beyond consumers, the purchase is a potentially neat fit for a lender to small businesses.

Analysts Still Expect Upside

With all the numbers and news to digest, analysts remain broadly bullish on the company, though some lowered their targets after the first quarter results.

As of now, the consensus rating on the stock is Moderate Buy, with an average price target of $258.14 implying roughly a one-third upside from current levels near $190. Price targets for 12 months range from $215 at the more cautious end to $310 at the most optimistic.

An agreement to pay $425 million to settle a class action suit alleging that Capital One had practiced deceptive marketing tactics also knocked the stock price in late April.

Investors Face a High-Risk Bet

For investors, there’s obviously still much to consider. Capital One is a high-conviction bet wrapped in genuine near-term uncertainty. For investors with a two-year time horizon and a stomach for volatility, the current price near $190 may prove to be an attractive entry point.

The 30+% decline from a recent peak may have already priced in a meaningful amount of bad news. If credit quality stabilizes and integration milestones are met, the stock has clear room to recover toward analyst targets.

But the risks remain. The company’s 1.7% dividend yield is unremarkable for income investors. And credit losses are still rising, while questions over two integrations remain. If you enjoy the uncertainty of predictions markets, this stock may be for you. READ THIS STORY ONLINE

The #1 stock to buy BEFORE the June S-1 filing (Ad)

When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early – while everyone else waits on the sidelines.

But one small infrastructure supplier – a critical piece Musk can’t scale the Colossus network without – is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost.GET THE SPACEX INFRASTRUCTURE STOCK NAME AND TICKER HERE

More Stories

• Apple Talks Just Changed Everything for Intel
• Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30%
• Are any of these 10 “toxic” stocks in your portfolio? (Ad)
• Just How Big a Problem Could Amazon’s Cash Burn Rate Be?
• BlackBerry Rewrites Its Own Operating System
• Years in the Making, AMD’s Upside Movement Has Just Begun
• Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore

The Night Owl is a financial newsletter that provides in-depth market analysis on stocks of interest to individual investors. Published by MarketBeat and Early Bird Publishing, The Night Owl is delivered around 9:00 PM Eastern Sunday through Thursday. If you give a hoot about the market, The Night Owl is the newsletter for you.

View as a Web Page

If you need assistance with your newsletter, feel free to email our U.S. based support team at contact@marketbeat.com.

Unsubscribe

© 2006-2026 MarketBeat Media, LLC. 
345 N Reid Pl., Suite 620, Sioux Falls, South Dakota 57103. U.S.A..

Check This Out: Your $29.97 book is free today(From Profits Run)

EVERYTHING 
ALL IN ONE 
PLACEHuge headlines. Epic matchups. Unmissable series. Watch every genre and relive it with highlights, replays, and shorts. Live or on-demand.

Start Streaming  BIG STORIES. 
BOLD PERSPECTIVES.FOX One puts your favorite personalities front and center. Search by name and jump straight into their must-see reactions.   TRY IT ALL. 
REGRET NOTHING.NewsSportsEntertainmentFOX Nation   AVAILABLE WHERE YOU WATCH   DOWNLOAD THE FOX ONE MOBILE APP   Follow Us:

Do you have a question? Click here to visit our Help Center. 
Please do not reply to this message. 

Unsubscribe | Manage Preferences | Terms of Use | Privacy Policy

™ and © 2026 Fox Media LLC. All rights reserved. 

Fox Digital Services LLC | PO Box 900, Beverly Hills, CA 90213-0900

Your recap for May 6, 2026 Top stories for youStock Market Today, May 6: Markets Break New Ground on Hopes for U.S.-Iran Peace DealWhy Walt Disney Stock Jumped 8.6% TodayDisney’s New CEO, Josh D’Amaro, Kicks Off His Tenure With a Bang, as Streaming Profits SoarDiving Into Josh D’Amaro’s Whole New WorldDisney (DIS) Q2 2026 Earnings TranscriptView more storiesMy portfolio highlightsDay Change   +1.26%Top gainersFLWS1-800-FLOWERS.COM3.93
+8.86%UURAFUcore Rare Metals4.21
+8.23%DISThe Walt Disney C…108.06
+7.54%Top losersXOM.MXExxon Mobil Corpo…2,563.0
-4.65%XOM.BAExxon Mobil Corpo…21,960.0
-4.65%JKHYJack Henry & …142.88
-4.33%Most activesDISThe Walt Disney C…108.06
+7.54%CSCOCisco Systems91.64
-2.82%XOMExxon Mobil148.69
-4.0%View your portfoliosUS market highlightsS&P 500
+1.46%Dow 30
+1.24%Nasdaq
+2.02%Russell 2000
+1.47%Crude Oil
-6.51%Top gainersFLEX
Flex Ltd.134.73
+39.69%HUT
Hut 8 Corp.108.94
+35.34%COMP
Compass, Inc.9.24
+27.27%Top losersPRIM
Primoris Services…101.23
-50.11%KVYO
Klaviyo, Inc. Ser…15.81
-32.23%TMDX
TransMedics Group…72.92
-23.19%Most activesNVDA
NVIDIA Corporation207.83
+5.77%INTC
Intel Corporation113.01
+4.46%SMCI
Super Micro Compu…34.66
+24.54%Yahoo Finance App: Portfolio performance, news and alerts, stock data and all you need in a finance app. Download now.

Privacy Policy | Customer Support | Unsubscribe

©2026 Yahoo Inc. All Rights Reserved.

770 Broadway, New York, NY 10003

Delivering World-Class Financial Research Since 1999

A 14-point plan… Still “too soon” for a deal… AMD’s blowout quarter… Tipping our hat to The Total Portfolio… Big tech is heavily reliant on AI startups… Hiring’s at a two-year high… Why the Fed’s focus is now back on inflation…

---

The deal was there, until it wasn’t…

Early this morning, Axios reported that the U.S. and Iran were close to agreeing on a “one-page memorandum of understanding” to end the Iran conflict. The memo included 14 “points” – like a 30-day negotiating period to finalize a deal and a temporary ban on Iranian uranium enrichment.

Shortly after, in a Truth Social post, President Donald Trump said the Strait of Hormuz will be “OPEN TO ALL” if Iran agrees to “give what has been agreed to.”

Those headlines sent stocks higher and oil crashing, with West Texas Intermediate (“WTI”) crude falling below $90 per barrel.

But just before 9 a.m. Eastern time, Trump told the New York Post that it’s “too soon” to make a deal with Iran.

Markets reversed a bit after those headlines, with stocks giving back some of their gains and WTI jumping back around $95 per barrel.

However, as we’ve covered in recent weeks, the market seems to believe that we’re getting closer to the end of the conflict.

Both the S&P 500 Index and Nasdaq Composite Index hit new all-time highs this afternoon, while the Dow Jones Industrial Average rose more than 1% – near its February high.

Elsewhere, the ‘melt up’ in semiconductors rages on…

Chipmaker Advanced Micro Devices (AMD) reported its first-quarter earnings yesterday after market close. The company beat Wall Street’s expectations on both earnings and revenue. Sales surged 38% in the quarter from the same period a year ago, with revenue in its data center and AI segment up 57% year over year.

CEO Lisa Su said that the company’s data-center business is now the “primary driver” of AMD’s growth. On the company’s earnings call, Su said that AMD expects to cross above $10 billion in quarterly revenue for its data-center business next year – about as much as the company’s total revenue at the end of the first quarter.

Total Portfolio subscribers heard it first…

In the March issue of The Total Portfolio, senior research analyst Brett Eversole wrote that AMD hadn’t taken off like other semiconductor stocks at the time, and it was trading near multiyear lows on a price-to-earnings basis.

It turned out to be a great call…

AMD’s shares are up around 20% today. And they’re up 112% since the Portfolio Solutions team recommended them in March.

AI companies are still spending…

Last week, Alphabet (GOOGL) announced that it will invest an initial $10 billion and up to $40 billion in AI startup Anthropic over the next few years.

Then, last night, digital news outlet the Information reported that Anthropic has agreed to spend $200 billion on chips and cloud computing from Alphabet’s Google over the next five years. Anthropic now makes up more than 40% of Google’s cloud-revenue backlog.

It’s simply more evidence of the “circular” financing we’ve seen in the AI space over the past year.

In short, companies like Microsoft (MSFT), Nvidia (NVDA), and Alphabet are investing billions of dollars in AI startups like OpenAI. These companies then use the funds to buy chips or computing power back from the investing company.

We’ve shared this image from Bloomberg in previous Digests, showing just how interconnected the AI-investment landscape is:

If just one of these companies falls through on its orders or investments, the entire web collapses.

As the Information founder Jessica Lessin shared on social platform X, OpenAI and Anthropic make up about half of Microsoft, Google, Amazon (AMZN), and Oracle’s (ORCL) collective cloud-services backlog. Take a look…

We’ve written a few times about how OpenAI is a bellwether of the AI bubble. Trouble for OpenAI could be the first signs of a peak.

And just last week, there were reports that OpenAI is falling behind on its revenue goals.

From the April 28 Digest…

Today is just one day, but if things are as bad at OpenAI as this latest report suggests, and if the company pulls out the rug on most or all of its spending promises, look out for the companies that have been known as the “AI leaders” in the past few years.

While its spending commitments aren’t as large as OpenAI’s, Anthropic has pledged to spend $330 billion on chips, computing, and other tools from Microsoft, Alphabet, and Amazon.

That’s enough to make Anthropic another company to watch in the AI space. If, like OpenAI, it falls short of its revenue goals, it won’t be able to meet its spending obligations.

If either – or both – of those startups has any hiccups in its growth story, it could take the wind right out of the AI boom’s sails.

In other news, hiring hits a two-year high…

In Tuesday’s Job Openings and Labor Turnover Survey, the Bureau of Labor Statistics reported that hires jumped to 5.55 million in March. That’s the most hires in a month since February 2024.

Payroll processor Automatic Data Processing (ADP) showed that the private sector added 109,000 jobs in its April jobs report. That was more than the 61,000 jobs added in March and beat Wall Street’s expectation for 84,000 jobs. By ADP’s measure, private payrolls have now increased every month since June 2025.

You can bet the Federal Reserve will be keeping its eye on this data.

During last month’s meeting – where the Fed held its benchmark federal-funds rates steady – three voters wanted to take out language in the Fed’s post-meeting statement that suggested a rate cut could still be appropriate.

If the labor market is stable and adding jobs, the economy doesn’t need rate cuts for support. Instead, the Fed could turn its focus solely back to inflation, which is rising at its fastest pace since May 2023.

According to CME Group’s FedWatch Tool, traders see a higher chance of a rate hike than a rate cut by the end of 2026.

The Fed will meet again in June, which will likely mark the first meeting for Kevin Warsh as the new Fed chair. If Warsh doesn’t show an inclination to cut rates, he could find himself in Trump’s crosshairs (Trump has repeatedly criticized Powell for not lowering rates). We could also see some market volatility as investors reprice stocks based on a higher-rate environment.

But there will be a lot more data to come between now and June – including Friday’s labor market report.

---

Recommended Links:

Until Midnight: Watch a Replay of the ‘Dark AI Summit’

Thousands of people tuned in for 50-year Wall Street legend Marc Chaikin and Silicon Valley investor Jeff Brown’s “Dark AI Summit.” These two financial legends shared what they believe could be the biggest danger facing investors today… a paradigm shift creating a stunning opportunity for investors who understand what’s happening. They also reveal the name of the new AI company whose technology they say will be essential to averting a crisis in 2026, including how you can take a stake in this private firm right now through your brokerage account, before it goes public. Click here to watch a free replay of the “Dark AI Summit.”

---

This Tech Could Be Bigger Than Apple, Amazon, and Microsoft Combined

A breakthrough tech backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang could soon be worth more than the stocks of Apple, Microsoft, and Amazon – combined. It’s likely the only answer to a $33 trillion problem… but most people don’t know it exists. A man who has consulted for the Pentagon and FBI just flew into a heavily secured site to get the full story and discover the stocks involved. Click here to see this tech with your own eyes – and learn how you could invest in the companies that own it.

---

New 52-week highs (as of 5/5/26): ABB (ABBNY), Atlas Energy Solutions (AESI), Amazon (AMZN), Air Products and Chemicals (APD), Broadcom (AVGO), CBOE Global Markets (CBOE), Ciena (CIEN), Cisco Systems (CSCO), DigitalOcean (DOCN), DXP Enterprises (DXPE), Ecovyst (ECVT), Emcor (EME), iShares MSCI Emerging Markets ex China Fund (EMXC), EnerSys (ENS), iShares MSCI South Korea Fund (EWY), Cambria Emerging Shareholder Yield Fund (EYLD), FirstCash (FCFS), Flex LNG (FLNG), Alphabet (GOOGL), Helmerich & Payne (HP), Hewlett Packard Enterprise (HPE), iShares Convertible Bond Fund (ICVT), Intel (INTC), KraneShares Bosera MSCI China A 50 Connect Index Fund (KBA), KraneShares Global Humanoid Robotics and Physical AI Index Fund (KOID), Keyence (KYCCF), Lumentum (LITE), Marathon Petroleum (MPC), Nucor (NUE), Invesco WilderHill Clean Energy Fund (PBW), ProShares Ultra Technology (ROM), USCF SummerHaven Dynamic Commodity Strategy No K-1 Fund (SDCI), U.S. Global Sea to Sky Cargo Fund (SEA), Solstice Advanced Materials (SOLS), State Street SPDR Portfolio S&P 500 Value Fund (SPYV), and State Street SPDR S&P Semiconductor Fund (XSD).

In today’s mailbag, feedback on yesterday’s Digest, which discussed rising gas prices… and another reply to a question recently raised by a subscriber in the mail… Do you have a comment or question? As always, e-mail us at feedback@stansberryresearch.com.

“[Yesterday you wrote] ‘… pity the Californians paying $6.13 per gallon of regular gas… ‘ Well, here in the UK we are paying a minimum of £1.55 per litre for gas (or petrol as we call it). That is [around $8.50] per gallon. Diesel is [near $10.50] per gallon. How do you like that?” – Subscriber S.J.I.

“In answer to your question: What would I give up [to help lower government spending], Let me say this: Long, long ago (I’m really old, see) in civics class we were taught that the federal government had two basic jobs – to provide for the common defense and to protect our liberties within the union. Sometimes those things (and others) get partnered with state governments, for example building and maintaining roads which is mostly a state responsibility, but with the invention of the interstate road system, now the federal government gets involved. Protecting liberties is mostly done through the courts which encompasses both local, state and federal systems including prison, parole, etc.

“But in the last 50 years or so and especially in the last 25, we (meaning the U.S. collectively) have expanded the scope of both the federal and state governments into a Great Big Expensive Babysitter. And the younger a person is, the more they seem to be willing to embrace the sitter.

“I don’t need anything from government except the military, the court system (which I haven’t needed yet, thank God) and the infrastructure built and maintained – a duty of which both the feds and the states do a terrible job.” – Stansberry Alliance member Jacqueline G.

All the best,

Nick Koziol
Baltimore, Maryland
May 6, 2026

---

Stansberry Research Top 10 Open Recommendations

Top 10 highest-returning open stock positions across all Stansberry Research portfolios. Returns represent the total return from the initial recommendation.InvestmentBuy DateReturnPublicationMSFT
Microsoft11/11/101,367.8%Retirement MillionaireMSFT
Microsoft02/10/121,328.0%Stansberry’s Investment AdvisoryCIEN
Ciena10/20/22861.1%Stansberry Innovations ReportGOOGL
Alphabet12/15/16856.8%Retirement MillionaireADP
Automatic Data Processing10/09/08814.8%Extreme ValueBRK.B
Berkshire Hathaway04/01/09759.2%Retirement MillionaireALS-T
Altius Minerals03/26/09667.8%Extreme ValueLITE
Lumentum04/15/21626.2%Stansberry Innovations ReportWRB
W.R. Berkley03/15/12617.8%Stansberry’s Investment AdvisorySII
Sprott01/11/18585.5%Extreme Value

Please note: Securities appearing in the Top 10 are not necessarily recommended buys at current prices. The list reflects the best-performing positions currently in the model portfolio of any Stansberry Research publication. The buy date reflects when the editor recommended the investment in the listed publication, and the return shows its performance since that date. To learn if a security is still a recommended buy today, you must be a subscriber to that publication and refer to the most recent portfolio.

---

Top 10 Totals3Extreme ValueFerris3Retirement MillionaireDoc2Stansberry Innovations ReportEngel2Stansberry’s Investment AdvisoryPorter

---

Top 5 Crypto Capital Open Recommendations

Top 5 highest-returning open positions in the Crypto Capital model portfolioInvestmentBuy DateReturnPublicationBTC/USD
Bitcoin11/27/182,053.2%Crypto CapitalWSTETH/USD
Wrapped Staked Ethereum12/07/181,913.5%Crypto CapitalONE/USD
Harmony12/16/191,009.8%Crypto CapitalPOL/USD
Polygon02/26/21642.8%Crypto CapitalQRL/USD
Quantum Resistant Ledger01/19/21453.5%Crypto Capital

Please note: Securities appearing in the Top 5 are not necessarily recommended buys at current prices. The list reflects the best-performing positions currently in the Crypto Capital model portfolio. The buy date reflects when the recommendation was made, and the return shows its performance since that date. To learn if it’s still a recommended buy today, you must be a subscriber and refer to the most recent portfolio.

---

Stansberry Research Hall of Fame

Top 10 all-time, highest-returning closed positions across all Stansberry portfoliosInvestmentDurationGainPublicationNvidia (NVDA)^*5.96 years1,466%Venture Tech.Microsoft (MSFT)^12.74 years1,185%Retirement MillionaireInovio Pharma. (INO)^1.01 years1,139%Venture Tech.Rocket Lab (RKLB)^2.35 years1,034%Venture Tech.Seabridge Gold (SA)^4.20 years995%Sjug Conf.Berkshire Hathaway (BRK-B)^16.13 years800%Retirement MillionaireIntellia Therapeutics (NTLA)1.95 years775%Amer. MoonshotsRite Aid 8.5% bond4.97 years773%True IncomePNC Warrants (PNC-WS)6.16 years706%True Wealth SystemsMaxar Technologies (MAXR)^1.90 years691%Venture Tech.

^ These gains occurred with a partial position in the respective stocks.
* Editor Dave Lashmet closed the first leg of this Nvidia position in November 2016 for a gain of about 108%. Then, he closed the second leg in July 2020 for a 777% return. And finally, in May 2022, he booked a 1,466% return on the final leg. Subscribers who followed his advice on Nvidia could’ve recorded a total weighted average gain of more than 600%.

---

Stansberry Research Crypto Hall of Fame

Top 5 highest-returning closed positions in the Crypto Capital model portfolioInvestmentDurationGainAnalystBand Protocol (BAND)0.31 years1,169%Crypto CapitalTerra (LUNA)0.41 years1,166%Crypto CapitalPolymesh (POLYX)3.84 years1,157%Crypto CapitalFrontier (FRONT)0.09 years979%Crypto CapitalBinance Coin (BNB)1.78 years963%Crypto Capital

You have received this e-mail as part of your subscription to Stansberry Digest. If you no longer want to receive e-mails from Stansberry Digest click here.

Published by Stansberry Research.

You’re receiving this e-mail at pahovis@aol.com. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice.

© 2026 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or stansberryresearch.com.

Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors.

Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation.

This work is based on SEC filings, current events, interviews, corporate press releases, and what we’ve learned as financial journalists. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility.

To view this email as a web page, click here

Dear Peter,

After a month of relative peace during the ceasefire (although attacks still continued, especially in northern Israel), the bomb shelters have been reopened in preparation for the return of open war. The demonic Jew-hatred that drives the leaders of Iran is not satisfied with death and destruction of thousands…they want Israel completely destroyed. We have received a generous matching gift challenge that will double your gift to help twice as many people—so please be as generous as you can when you send your gift today.

The situation is urgent. So many people have lost homes, family members, and even everything they owned in the missile attacks. I’m thinking about families like the Cohens. They buried six family members on the day their son was supposed to have his bar mitzvah. We helped them with the medical bills, buying clothing, and more, and they were so grateful. But there are so many others in urgent need.

The people of Israel are suffering greatly right now, and while they need our prayers, they also need our help. Together we are answering the command of God, “Comfort ye My people.” Together we are telling, and more importantly showing, the people of Israel that they are not alone. Please send your most generous gift today and share this with everyone you know. 

Make a donation here:  https://give.foz.org

Your support of the Friends of Zion today allows us to comfort the people of Israel who have survived the terrorist attacks, minister to the families of the hostages, continue to purchase and deliver food, medicine, clothing, and other necessities of life for the poor Holocaust survivors and refugees of Ukraine, continue to operate the Friends of Zion Museum, and to meet urgent humanitarian needs among the poor Jewish people living in Israel. Thank you so much for being part of this vital worldwide prayer movement. 

Your ambassador to Jerusalem,

Dr. Mike Evans

Make an online donation here:  https://give.foz.org

Friends of Zion | PO BOX 30000, Phoenix, AZ 85046 | memi@foz.org | 1-888-390-7946

This email was sent to peterhovis@icloud.com. If you’d rather not receive emails like this anymore, let us know.

Hello Peter,

Open Bottle Thursday

May 7, 2026

Ruffino Riserva Ducale Oro

Chianti Classico

Gran Selezione 2021

(Tuscany, Italy)

This Might Be Our Biggest Wine Deal Yet!

Our thoughts…this bottle represents the pinnacle of Chianti classification, a true Gran Selezione crafted exclusively from estate-owned fruit, aged a minimum of 30 months, and produced from low-yield vineyards for maximum concentration and character. Ruffino helped introduce American drinkers to the concept of reserve-level Chianti—and moved it beyond the iconic straw basket into the realm of world-class fine wine. In the glass, it shows a deep ruby color with garnet hues and an unmistakably Tuscan bouquet of violet, cherry, and plum, layered with chocolate, cinnamon, and clove. The palate is both powerful and refined, with beautifully integrated tannins and vibrant fruit wrapped in spice, leading to a long, elegant finish marked by notes of coffee and dark chocolate.

95 points – James Suckling

“An elegant and forthright Gallo Nero with a precise nose of red cherries, eucalyptus and licorice with balsamic nuances. A lush and supple palate with a full body and dense, velvety tannins that are precise and spicy. Crisp yet integrated acidity in the finish. Savory aftertaste. Drink or hold.”

About the Winery…Ruffino is one of Tuscany’s most historic and influential producers, founded in 1877 and instrumental in bringing Chianti to international prominence—especially in the United States. The estate helped elevate the reputation of Chianti from its humble beginnings in straw-covered bottles to a globally respected fine wine category, pioneering quality-focused production and reserve-level expressions. Today, Ruffino remains deeply rooted in Tuscany, sourcing from estate vineyards across the region and continuing a legacy of combining tradition with modern precision to craft wines that reflect the authenticity and elegance of Chianti Classico.

Quantities are limited, so order now for this special…

no need to wait until Thursday!

Tasting time on Thursday: 3 – 7:30 PM

Special Sale Pricing

Our Regular Price: $42.99

Buy 1-5 bottles: $31/bottleORDER 1-5 BOTTLES

Buy 6-11 bottles: $27/bottleORDER 6-11 BOTTLES

Buy 12+ bottles: $22/bottleORDER 12+ BOTTLES

Thank you for shopping local!

Kate, Donna P., Heidi, Valerie, Beth, Melanie, Mari, Patty, Donna B., Matt, Bill, Steve, Rande and Mike

The Wine Cabinet

1416 North Point Village Center

Reston, VA 20194

(703) 668-9463 (WINE)

Shop Hours

Mon – Wed: 11 AM – 7 PM

Thu – Sat: 11 AM – 8 PM

Sun: 11 AM – 6 PM

View email in browser
The Wine Cabinet · 1416 Northpoint Village Ctr · Reston, VA 20194-1190 · USA
update your preferences or unsubscribe

Two of our latest collections are now available in-store at State Forty Eight.

Our National Parks Collection is all about getting outside, appreciating what’s around us, and representing the places that make Arizona special.

Our military-inspired collection is a simple, thoughtful way to wear respect—created for those who feel connected to the meaning behind it.

Both are now ready to see, feel, and try on in person.

If you’re nearby, come through and spend some time with us. We’ve been continuing to make improvements to the space and experience every week, and we’d love for you to check it out.

Prefer to shop from home? You can still grab your favorites online while supplies last.

Whether you’re picking up a gift or just adding something you’re proud to wear, we’re grateful you choose to do it with us.

Thank you for continuing to support a hometown brand that’s built on love for Arizona and the people in it.SHOP NOW

 

 SHOP NOW

 

 

No longer want to receive these emails? Unsubscribe.
State Forty Eight 3245 N. Arizona Ave. Suite E4 Chandler, AZ 85225

Open in Browser

You are subscribed to this email as: peterhovis@icloud.com

  

You’re not currently a member. When news happens, Phoenix New Times is there —
Your support strengthens our coverage.  CONTRIBUTE NOW

 

things to do

 

Treat mom to a special Mother’s Day meal at these Phoenix restaurants

Mother’s Day is on Sunday, and at most restaurants, reservations are required. Here’s where to book your spot.

By Georgann YaraREAD MORE 

Michelin-recommended taquerias pop-up at Chase Field

Three acclaimed Mexico City taco makers will serve in downtown Phoenix for three days only.

By Sara Crocker 

Usher, Chris Brown announce stadium tour with Glendale date

R&B superstars incoming.

By Jennifer Goldberg 

Where to eat near the stadiums in downtown Phoenix

Catching a game at Chase Field or heading to a show at Mortgage Matchup Center? Here’s where to fuel the fun.

By Tirion Boan 

Photos: Foodies braved the heat for creative eats at giant Phoenix food festival

Despite 100 degree temperatures, fans flocked to FoodieLand last weekend. Take a look at the action.

By Brigette Doby MORE EVENT STORIES

UPCOMING EVENTS

ROBERT LESTER FOLSOM WITH SPECIAL GUEST KASSI VALAZZA

Valley Bar

Wed., May. 6 | 7:30 PMTICKETS

Raye

Arizona Financial Theatre

Thu., May. 7 | 7:00 PMTICKETS

JENSEN MCRAE – GOD HAS A HITMAN TOUR

Crescent Ballroom

Thu., May. 7 | 8:00 PMTICKETS

Tripping Daisy

The Rebel Lounge

Thu., May. 7 | 8:00 PMTICKETS

ARM’S LENGTH: “THERE’S A WHOLE WORLD…” NORTH AMERICAN TOUR 2026

Crescent Ballroom

Fri., May. 8 | 7:00 PMTICKETS

El Ten Eleven

The Rebel Lounge

Fri., May. 8 | 8:00 PMTICKETSMORE THINGS TO DO

Love New Times? Thanks to a recent Google update, you can now select us as a preferred source to see our stories first in search results. Thank you in advance for your ongoing support of local journalism. 

Manage Profile | Unsubscribe

To ensure you receive our emails, please add inbox@phoenixnewtimes-insider.com to your address book.
You are receiving this advertisement newsletter because you have signed up on our website or at an event, participated in a promotion, or purchased a ticket to an event. Thank you for your patronage.
© 2026 Phoenix New Times, LLC. All rights reserved.
1201 E. Jefferson
Phoenix, AZ 85034